pancreatitis na ERCP infection of pancreas pancreatitis
Conditions
Interventions
The intervention group receives 2 gram ceftazidim solution in a 10ml syringe
intravenous before the ERCP. The control group receives sodium chloride (NaCl)
in a 10ml syringe intravenous before the E
Sponsors
Elisabeth-Tweesteden ziekenhuis
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: • Patients undergoing an elective ERCP at the Elisabeth-TweeSteden hospital Tilburg, who are willing to participate and give informed consent. • Have the minimum age of 18 years or older.
Exclusion criteria
Exclusion criteria: • Patients who experience a chronic or acute pancreatitis. • Patients with known pancreas malignancy. • Patients treated with antibiotics/ cholangitis. • Patients with any contraindication or with a known allergy to ceftazidime or to any other cephalosporin antibiotics. • History of severe hypersensitivity (e.g. anaphylactic reaction) to any other type of beta-lactam antibacterial agent (penicillins). • Patients who are pregnant, lactating or planning pregnancy while enrolled in the study. • Patients who are unsuitable for inclusion in the study in the opinion of the investigator for any reason that may compromise the subject*s safety or confound data interpretation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary study parameter is the incidence of post-ERCP pancreatitis the day after the ERCP. Post-ERCP pancreatitis will be defined as the presence of abdominal pain and an increased lipase according to the Cotton criteria. Delayed post-ERCP pancreatitis will be assessed until 4 weeks after the procedure. | — |
Secondary
| Measure | Time frame |
|---|---|
| see primary study parameters | — |
Countries
Netherlands
Outcome results
None listed